Investors

Recent Releases

September 1, 2026

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and

August 31, 2026

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing

August 31, 2026

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada GAITHERSBURG, Md., Aug.